Skip to content
ClinCalc Pro
Menu
Antidiabetic — Insulin

Insulin (various)

Brand names: NovoRapid (aspart), Humalog (lispro), Lantus (glargine), Actrapid (soluble)

Insulin preparations (various rapid-, short-, intermediate- and long-acting types) used in children, principally for type 1 diabetes mellitus, to provide physiological glucose control.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Replaces or supplements endogenous insulin, promoting cellular glucose uptake, hepatic glycogen synthesis and suppression of gluconeogenesis and lipolysis to lower blood glucose.

Prescribing in practice

  • Hypoglycaemia is the principal hazard; ensure rapid-acting glucose and a treatment plan are always available and that the family can recognise and manage it.
  • Different insulin types and brands are not interchangeable, so specify the exact preparation and device and avoid inadvertent substitution.
  • Match insulin type, timing and dose to carbohydrate intake and activity, adjusting during illness using sick-day rules and a children's formulary/local diabetes protocol.

Monitoring

Monitor capillary or continuous glucose, HbA1c, injection or infusion sites and growth, with ketone checking during illness or hyperglycaemia.

Counselling the patient

  • Teach the child and family to recognise and treat hypoglycaemia and to always carry fast-acting glucose.
  • Rotate injection sites to prevent lipohypertrophy, which alters insulin absorption.
  • Follow sick-day rules, continue insulin during illness and check ketones when unwell or glucose is high.

Evidence & guidelines

Insulin replacement is the cornerstone of paediatric type 1 diabetes management per NICE guidance (NG18).

Reference: BSPED DKA Guidelines 2020; ISPAD Guidelines 2022; NICE NG18; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.